These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37330413)

  • 61. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium.
    Mir MC; Marchioni M; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; McGrath JS; Kassouf W; Dall'Era MA; Sridhar SS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand D; Black PC
    Eur Urol Focus; 2021 Nov; 7(6):1347-1354. PubMed ID: 32771446
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Pathological pelvic lymph node involvement in muscle-invasive bladder cancer patients treated with radical cystectomy: A narrative review].
    Gabriel PE; Pinar U; Parra J; Vaessen C; Mozer P; Chartier-Kastler E; Rouprêt M; Seisen T
    Prog Urol; 2023 Mar; 33(3):145-154. PubMed ID: 36604248
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
    Lu J; Feng Y; Guo K; Sun L; Ruan S; Zhang K
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):25. PubMed ID: 38252173
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
    Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
    Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
    Zhang L; Wu B; Zha Z; Qu W; Zhao H; Yuan J
    BMC Cancer; 2019 Jul; 19(1):716. PubMed ID: 31324162
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.
    Leow JJ; Martin-Doyle W; Rajagopal PS; Patel CG; Anderson EM; Rothman AT; Cote RJ; Urun Y; Chang SL; Choueiri TK; Bellmunt J
    Eur Urol; 2014 Jul; 66(1):42-54. PubMed ID: 24018020
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
    Christensen E; Birkenkamp-Demtröder K; Sethi H; Shchegrova S; Salari R; Nordentoft I; Wu HT; Knudsen M; Lamy P; Lindskrog SV; Taber A; Balcioglu M; Vang S; Assaf Z; Sharma S; Tin AS; Srinivasan R; Hafez D; Reinert T; Navarro S; Olson A; Ram R; Dashner S; Rabinowitz M; Billings P; Sigurjonsson S; Andersen CL; Swenerton R; Aleshin A; Zimmermann B; Agerbæk M; Lin CJ; Jensen JB; Dyrskjøt L
    J Clin Oncol; 2019 Jun; 37(18):1547-1557. PubMed ID: 31059311
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
    Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
    Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
    Schardt J; Roth B; Seiler R
    World J Urol; 2019 Sep; 37(9):1759-1765. PubMed ID: 30392011
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
    Boegemann M; Krabbe LM
    Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
    [TBL] [Abstract][Full Text] [Related]  

  • 73. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Witjes JA; Bruins HM; Cathomas R; Compérat EM; Cowan NC; Gakis G; Hernández V; Linares Espinós E; Lorch A; Neuzillet Y; Rouanne M; Thalmann GN; Veskimäe E; Ribal MJ; van der Heijden AG
    Eur Urol; 2021 Jan; 79(1):82-104. PubMed ID: 32360052
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
    Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P
    Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
    Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
    Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Circulating Tumor DNA and Survival in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Dickinson K; Sharma A; Agnihotram RV; Altuntur S; Park M; Meterissian S; Burnier JV
    JAMA Netw Open; 2024 Sep; 7(9):e2431722. PubMed ID: 39235812
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.
    Kluth LA; Black PC; Bochner BH; Catto J; Lerner SP; Stenzl A; Sylvester R; Vickers AJ; Xylinas E; Shariat SF
    Eur Urol; 2015 Aug; 68(2):238-53. PubMed ID: 25709027
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.
    Yuan SQ; Nie RC; Huang YS; Chen YB; Wang SY; Sun XW; Li YF; Liu ZK; Chen YX; Yao YC; Xu Y; Qiu HB; Liang Y; Wang W; Liu ZX; Zhao Q; Xu RH; Zhou ZW; Wang F
    Cancer Commun (Lond); 2023 Dec; 43(12):1312-1325. PubMed ID: 37837629
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.
    Vashistha V; Quinn DI; Dorff TB; Daneshmand S
    BMC Cancer; 2014 Dec; 14():966. PubMed ID: 25515347
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.
    Taliento C; Morciano G; Nero C; Froyman W; Vizzielli G; Pavone M; Salvioli S; Tormen M; Fiorica F; Scutiero G; Scambia G; Giorgi C; Greco P; Pinton P
    Int J Gynecol Cancer; 2024 Jun; 34(6):906-918. PubMed ID: 38658022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.